Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00521404 · ClinicalTrials.gov registry record · Phase 2
Open-label Study of CS-1008 for Subjects With Untreated and Unresectable Pancreatic Cancer
A Phase 2 study of Pancreatic Cancer, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
- 12
- Study locations
NCT00521404 is a Phase 2 study of Pancreatic Cancer that has completed, run by Daiichi Sankyo. The registered enrollment target is 65 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (83% lower). The trial reports 12 study locations across 10 states.
The verdict
NCT00521404, a Phase 2 study of Pancreatic Cancer, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
- 12
- Study locations
Study Summary
Phase 2 study to determine the efficacy and safety of CS-1008 when given with gemcitabine to subjects with previously untreated and unresectable (unable to be surgically removed) or metastatic (spread to other areas beyond the pancreas) pancreatic cancer.
Conditions Studied
Interventions
- DRUG gemcitabine
- DRUG CS-1008 (humanized anti-DR5 antibody)
Study Locations (12)
Georgia
- - Atlanta
- Georgia Cancer Specialists - Tucker
Tennessee
- - Chattanooga
- - Nashville
Alabama
- - Birmingham
District of Columbia
- - Washington D.C.
Florida
- - Fort Myers
Illinois
- - Decatur
Minnesota
- - Minneapolis
Ohio
- - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2007-08-15 |
| Est. Completion | 2010-08-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00521404
The ClinicalTrials.gov registry entry for NCT00521404 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (83% lower). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which gemcitabine is the first listed.
NCT00521404 reports 12 study locations spanning 10 distinct geographic areas - top geographies include Georgia, Tennessee, Alabama.
Frequently Asked Questions
What is clinical trial NCT00521404 about?
NCT00521404 is a clinical study titled "Open-label Study of CS-1008 for Subjects With Untreated and Unresectable Pancreatic Cancer". Phase 2 study to determine the efficacy and safety of CS-1008 when given with gemcitabine to subjects with previously untreated and unresectable (unable to be surgically removed) or metastatic (spread to other areas beyond the pancreas) pancreatic cancer.
What is the current status of trial NCT00521404?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2007-08-15. Estimated completion is 2010-08-20.
What conditions does trial NCT00521404 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT00521404?
The interventions under investigation include: gemcitabine (DRUG), CS-1008 (humanized anti-DR5 antibody) (DRUG).
Who is sponsoring clinical trial NCT00521404?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00521404 being conducted?
This trial has 12 study locations across Alabama, District of Columbia, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
RECRUITING · Phase 2
-
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.